Teva will able to market a generic version of the anticoagulant in the US in June 2019, even though its patents expire in 2028.
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) has settled a patent infringement lawsuit with The Medicines Company (Nasdaq: MDCO) over generic Angiomax, an anticoagulant. Under the settlement, Teva will able to market generic Angiomax in the US in June 2019, even though its patents expire in 2028.
The Medicines Company sued Teva with the US District Court for the District of Delaware for patent infringement. Teva inherited the case when it acquired Barr Pharmaceuticals and its Croat affiliate Pliva Hrvatska doo.
Teva's share price closed at $37.22 on Nasdaq on Friday, giving a market cap of $33.2 billion, and rose 0.1% by mid-afternoon on the TASE today to NIS 140.80.
Published by Globes [online], Israel business news - www.globes-online.com - on October 3, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011